MRC1 and cancer: Cancers in CMMRD patients are refractory to agents like temozolomide and mercaptopurines which need an intact MMR machinery for their cytotoxic action, but these tumors uniformly harbor high tumor mutation (TMB) and microsatellite indel (MSI) burden, making them amenable to immune checkpoint inhibition (ICI)8–13.